CLSA Trims SINO BIOPHARM (01177) Target Price to HK$9.8, Sees Next Growth Phase Driven by New Launches and Platform Expansion

Stock News03-30

CLSA released a research report indicating that SINO BIOPHARM (01177) reported revenue and earnings below expectations for the second half of fiscal year 2025. Revenue increased 10% year-on-year, while profit declined 40% year-on-year. Looking ahead, the firm expects the group's continuous rollout of new products and enhanced sales of innovative drugs to remain key growth drivers. Considering the weak performance in the second half of fiscal 2025 and the normalization of contributions from business development revenue, CLSA has lowered its revenue forecasts for the current and next fiscal years by 3% to 5%, and reduced profit forecasts by 11% to 13%. The target price has been cut from HK$9.2 to HK$8.9, while maintaining an "Outperform" rating. CLSA projects revenue growth rates of 13%, 14%, and 12% for fiscal years 2026, 2027, and 2028, respectively, and anticipates net profit growth of 15% and 13% for fiscal 2027 and 2028. The launch of new innovative drugs and expansion of indications are expected to be primary growth catalysts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1176442987?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 16:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176442987","market":"sh","top_or_hot":-1,"title":"CLSA Trims SINO BIOPHARM (01177) Target Price to HK$9.8, Sees Next Growth Phase Driven by New Launches and Platform Expansion","media":"Stock News","content":"<p>CLSA released a research report indicating that SINO BIOPHARM (01177) reported revenue and earnings below expectations for the second half of fiscal year 2025. Revenue increased 10% year-on-year, while profit declined 40% year-on-year. Looking ahead, the firm expects the group's continuous rollout of new products and enhanced sales of innovative drugs to remain key growth drivers. Considering the weak performance in the second half of fiscal 2025 and the normalization of contributions from business development revenue, CLSA has lowered its revenue forecasts for the current and next fiscal years by 3% to 5%, and reduced profit forecasts by 11% to 13%. The target price has been cut from HK$9.2 to HK$8.9, while maintaining an \"Outperform\" rating. CLSA projects revenue growth rates of 13%, 14%, and 12% for fiscal years 2026, 2027, and 2028, respectively, and anticipates net profit growth of 15% and 13% for fiscal 2027 and 2028. The launch of new innovative drugs and expansion of indications are expected to be primary growth catalysts.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLSA Trims SINO BIOPHARM (01177) Target Price to HK$9.8, Sees Next Growth Phase Driven by New Launches and Platform Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLSA Trims SINO BIOPHARM (01177) Target Price to HK$9.8, Sees Next Growth Phase Driven by New Launches and Platform Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-30 16:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLSA released a research report indicating that SINO BIOPHARM (01177) reported revenue and earnings below expectations for the second half of fiscal year 2025. Revenue increased 10% year-on-year, while profit declined 40% year-on-year. Looking ahead, the firm expects the group's continuous rollout of new products and enhanced sales of innovative drugs to remain key growth drivers. Considering the weak performance in the second half of fiscal 2025 and the normalization of contributions from business development revenue, CLSA has lowered its revenue forecasts for the current and next fiscal years by 3% to 5%, and reduced profit forecasts by 11% to 13%. The target price has been cut from HK$9.2 to HK$8.9, while maintaining an \"Outperform\" rating. CLSA projects revenue growth rates of 13%, 14%, and 12% for fiscal years 2026, 2027, and 2028, respectively, and anticipates net profit growth of 15% and 13% for fiscal 2027 and 2028. The launch of new innovative drugs and expansion of indications are expected to be primary growth catalysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1176442987","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176442987","pubTimestamp":1774860637,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLSA released a research report indicating that SINO BIOPHARM (01177) reported revenue and earnings below expectations for the second half of fiscal year 2025. Revenue increased 10% year-on-year,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","01177":"中国生物制药","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"里昂证券下调中国生物制药(01177)目标价至9.8港元，预计新产品上市和平台扩张将推动下一个增长阶段","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"CLSA released a research report indicating that SINO BIOPHARM (01177) reported revenue and earnings below expectations for the second half of fiscal year 2025. Revenue increased 10% year-on-year, while profit declined 40% year-on-year. Looking ahead, the firm expects the group's continuous rollout of new products and enhanced sales of innovative drugs to remain key growth drivers. Considering the weak performance in the second half of fiscal 2025 and the normalization of contributions from business development revenue, CLSA has lowered its revenue forecasts for the current and next fiscal years by 3% to 5%, and reduced profit forecasts by 11% to 13%. The target price has been cut from HK$9.2 to HK$8.9, while maintaining an \"Outperform\" rating. CLSA projects revenue growth rates of 13%, 14%, and 12% for fiscal years 2026, 2027, and 2028, respectively, and anticipates net profit growth of 15% and 13% for fiscal 2027 and 2028. The launch of new innovative drugs and expansion of indications are expected to be primary growth catalysts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1176442987","isCrawlerRequest":true}